Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.
相关临床试验
12
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
2
16.7%
已完成
7
58.3%
终止
3
25.0%
暂无批准数据
- Aera Therapeutics appointed William Querbes, Ph.D., as chief scientific officer to lead advancement of genetic medicine delivery platforms and pipeline expansion. - Dr. Querbes brings over 20 years of experience in genetic medicines development, including leading the discovery of GIVLAARI, the first FDA-approved RNAi therapeutic using GalNAc conjugate technology. - The appointment strengthens Aera's leadership team as the company develops proprietary lipid and protein nanoparticle platforms to expand genetic medicine applications across multiple therapeutic areas.
- Synlogic's engineered probiotic SYNB1934 demonstrated a significant 34% reduction in phenylalanine levels in phenylketonuria patients during Phase 2 trials, outperforming its predecessor SYNB1618. - The experimental therapy showed a 42% reduction in plasma phenylalanine among responders, with 60% of patients achieving clinically meaningful improvements in their condition. - Phase 3 trials for SYNB1934 are scheduled to begin in early 2023, offering potential hope for PKU patients who have limited treatment options with current therapies.
